Terug naar bedrijfspagina

Nieuws over Celyad Oncology

05/04/2024 Celyad - Letter to 2024 Shareholders (05.04.2024)

04/04/2024 Celyad Oncology - publie ses résultats financiers pour l'année 2023 ainsi que les récents évènements marquants (04.04.2024)

09/02/2024 Celyad Oncology - announces intention to terminate SEC reporting obligations (09.02.2024)

17/01/2024 Celyad Oncology - provides fourth quarter 2023 business update and 2024 outlook (17.01.2024)

09/11/2023 Celyad Oncology - reports third quarter 2023 financial results and recent business highlights (09.11.2023)

05/09/2023 Celyad Oncology - Reports First Half 2023 Financial Results and Recent Business Highlights (05.09.2023)

16/05/2023 Celyad Oncology - announces receipt of Nasdaq delisting notice (16.05.2023)

05/05/2023 Celyad Oncology - reports first quarter 2023 financial results and recent business highlights (05.05.2023)

25/04/2023 Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price (24.04.23)

05/04/2023 Celyad Oncology - announces receipt of Nasdaq notice (05.04.2023)

24/03/2023 Celyad Oncology - reports full year 2022 financial results and recent business highlights (23.03.23)

24/03/2023 Celyad Oncology - appoints Georges Rawadi as its new CEO (24.03.23)

15/03/2023 Celyad Oncology - announces non-cash impairment (15.03.2023)

01/03/2023 CELYAD - Letter to Shareholders (01.03.2023)

09/02/2023 Celyad Oncology - announces the publication of data from its Phase 1 THINK study of CYAD-01 (09.02.2023)

03/02/2023 Celyad Oncology - provides fourth quarter 2022 business update and 2023 outlook (03.02.2023)

21/12/2022 Celyad Oncology - provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property (21.12.2022)

20/09/2022 Celyad Oncoloy - en Cellistic kondigen GMP Celtherapie Manufacturing Operations-transactie aan (20.09.2022)

05/08/2022 Celyad Oncology - Reports First Half 2022 Financial Results and Recent Business Highlights (05.08.2022)

01/08/2022 Celyad Oncology - Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial (01.08.2022)

06/05/2022 Celyad Oncology - Announces First Quarter 2022 Financial Results and Recent Business Highlights (06.05.2022)

25/03/2022 Celyad Oncology - Reports Full Year 2021 Financial Results and Recent Business Highlights (25.03.2022)

02/03/2022 Celyad Oncology - Announces Clinical Hold of CYAD-101-002 Phase 1b Trial (02.03.2022)

28/02/2022 Celyad Oncology - kondigt vrijwillige pauze aan van CYAD-101-002 Fase 1b-onderzoek (28.02.2022)

03/12/2021 Celyad Oncology - kondigt $ 32,5 miljoen private plaatsing aan bij Fortress Investment Group (03.12.2021)

17/11/2021 Celyad Oncology - Announces Third Quarter 2021 Financial Results and Recent Business Highlights (17.11.2021)

12/11/2021 Celyad Oncology: resents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design (12.11.2021)

11/11/2021 Celyad Oncology - Announces Third Quarter 2021 Financial Results and Recent Business Highlights (11.11.2021)

01/10/2021 Celyad Oncology - Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting (01.10.2021)

06/09/2021 2021 07 - Interview met ceo Filippo Petti

06/08/2021 Celyad - Reports First Half 2021 Financial Results and Recent Business Highlights (4.8.2021)

21/07/2021 Celyad Oncology - Presenteert Updates over Allogene CAR T Klinische Kandidaten en shRNA-gebaseerde Preklinische Concepten op de Onderzoek&Ontwikkeling Dag (21.07.2021)

10/05/2021 Celyad Oncology - Announces First Quarter 2021 Financial Results and Recent Business Highlights (10.05.2021)

07/05/2021 Celyad Oncology - Announces First Quarter 2021 Financial Results and Recent Business Highlights (07.05.2021)

01/04/2021 Celyad Oncology - Announces April 2021 Conference Schedule (01.04.2021)

25/03/2021 Celyad Oncology - Reports Full Year 2020 Financial Results and Recent Business Highlights (25.03.2021)

18/01/2021 Celyad - Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD101 in mCRC at ASCO-GI Symposium (persbericht 18.01.2021)

07/12/2020 Celyad - levert updates over allogene en autologe CAR T programma’s (07.12.2020)

03/08/2020 Celyad - Oncology kondigt de financiële resultaten van de eerste helft van 2020 aan samen met een conference call (3.8.2020)

14/07/2020 Celyad - Oncology kondigt FDA goedkeuring aan van IND aanvraag voor CYAD-211 (14.7.2020)

25/03/2020 Celyad - rapporteert de financiële resultaten voor het volledige jaar 2019 en geeft een zakelijke update (25.3.2020)

06/12/2019 Celyad Receives Additional €2.5 Million in Non-Dilutive Funding (6.10.2019)

29/03/2019 Celyad Reports Business Update and Full Year 2018 Financial and Operating Results (29.3.2019)

19/03/2019 Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline (19.3.2019)

07/01/2019 Celyad Outlines Key 2019 Priorities Including theAcceleration of the CYAD-01 Program in AML and MDS (7.1.2018)

04/12/2018 Celyad presenteert update van klinische studie (4.12.2018)

21/11/2018 Celyad geeft update over activiteiten derde kwartaal 2018 (21.11.2018)

04/10/2018 Celyad kondigt exclusieve overeenkomst aan voor het shRNA-platform van Horizon Discovery (4.10.2018)

28/09/2018 Celyad: Transparency Notification of Victory Capital Management Inc. (28.9.2018)

25/09/2018 Celyad neemt deel aan KBC en Leerink Partners conferenties (25.9.2018)

05/09/2018 Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy (5.9.2018)

23/08/2018 Celyad rapporteert financiële resultaten en operationele voortgang voor eerste semester 2018 (23.8.2018)

07/08/2018 Celyad benoemt Filippo Petti tot Chief Financial Officer (7.8.2018)

21/06/2017 Turbulentie in Belgische biotech: Celyad en ASIT Biotech (KBC Group, The Front Row)

26/10/2015 2015 09 - Interview met Christian Homsy ceo van Celyad

23/09/2013 2013 08 - Interview met ceo Christian Homsy